NCT01735955 2024-02-08Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyNovartisPhase 4 Completed57 enrolled 8 charts
NCT04333108 2023-05-06Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentAB SciencePhase 3 Unknown140 enrolled